^
    Back
    Association details:
    Biomarker:HER-2 A775_G776insYVMA
    Cancer:Lung Adenocarcinoma
    Drug:Tarlox (tarloxotinib bromide) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Clin Cancer Res
    Title:

    Tarloxotinib is a hypoxia-activated pan-HER kinase inhibitor active against a broad range of HER-family oncogenes

    Published date:
    12/22/2020
    Excerpt:
    Finally, a patient with lung adenocarcinoma harboring a HER2 exon 20 p.A775_G776insYVMA mutation demonstrated a dramatic clinical response to tarloxotinib.
    DOI:
    10.1158/1078-0432.CCR-20-3555